MindWalk Holdings
MindWalk Holdings - AI and Analytics-Driven Biologics Discovery
A proven innovator in the TechBio space, MindWalk Holdings has developed the lone bio-native AI platform applicable to biologics discovery. Rapidly deciphering biological complexities, the platform provides a customizable ecosystem for identifying and contextualizing complex datasets and sequences, as well as finding connections between lab research and demonstrated real-world applications. MindWalk Holdings’ transformative approach clarifies complex biology in ways that drive rapid drug discovery.
The MindWalk Holdings team has developed LensAI as a way of generating instant links between evidence and mapped elements within functional, structural, and literature contexts. It seamlessly examines 25 billion biological relationships, and in the process turns siloed data into actionable insights. Diversity and reproducibility are cornerstones of the platform, only the best candidates move forward into clinical trials.
In one representative application, MindWalk Holdings’ LensAI platform enabled ImmunoPrecise Antibodies, Ltd., to quickly move forward on a life-saving dengue vaccine program. Through LensAI, the company discovered and validated a uniquely conserved dengue epitope that has already advanced to pre-clinical manufacturing stages, including virus neutralization analysis and in vivo testing.
Contact
823 CONGRESS AVE, SUITE 300
Austin, TX US